Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. COPD occurs most often in older people, but can also affect people in their middle ages. It is a major cause of chronic morbidity and mortality globally. Many people suffer from this disease for years, and die from it or its complications, and it constitutes a substantial economic and social burden.
Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to COPD risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition, thereby acting as a driver for revenue growth. The share of mortality attributed to COPD is expected to increase in the coming decades, when compared with other chronic diseases such as heart disease and stroke.
The marketed products landscape comprises a wide range of treatment options, including bronchodilator combinations, bronchodilator and ICS combinations, bronchodilator monotherapies and PDE-4 inhibitors. However, the market is undergoing a gradual transition, away from bronchodilator and ICS therapies and towards targeted and triple combination drug treatments. The market is set to be driven by recently launched products, and the approval of novel drugs that will supplement current market leaders and offer greater therapeutic options.
For Full Report Visit@ http://www.acutemarketreports.com/report/copd-therapeutics-in-asia-pacific-markets
Scope
The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%.
- Bronchodilators and ICS dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the COPD market?
- Do branded therapies show continuous growth, and are they facing any competition from generics?
- How will branded therapies be affected by upcoming pipeline therapies?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
- What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?
Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
Various drivers and barriers will influence the market over the forecast period.
- What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?
- Bronchodilators and ICS dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the COPD market?
- Do branded therapies show continuous growth, and are they facing any competition from generics?
- How will branded therapies be affected by upcoming pipeline therapies?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
- What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?
Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
Various drivers and barriers will influence the market over the forecast period.
- What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?
For Full Report Visit@ http://www.acutemarketreports.com/report/copd-therapeutics-in-asia-pacific-markets
Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals."
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals."
For Full Report Visit@ http://www.acutemarketreports.com/report/copd-therapeutics-in-asia-pacific-markets
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 12
2.4.1 Pathophysiology 13
2.5 Diagnosis 13
2.6 Disease Stages 14
2.7 Prognosis 14
2.8 Treatment Options 15
2.8.1 Treatment Algorithm 16
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 12
2.4.1 Pathophysiology 13
2.5 Diagnosis 13
2.6 Disease Stages 14
2.7 Prognosis 14
2.8 Treatment Options 15
2.8.1 Treatment Algorithm 16
3 Marketed Products 18
3.1 Overview 18
3.2 Bronchodilator Combination Therapy 18
3.2.1 Brimica/Duaklir Genuair (aclidinium/formoterol) - AstraZeneca 18
3.2.2 Spiolto/Stiolto Respimat (tiotropium/olodaterol) - Boehringer Ingelheim 20
3.2.3 Ultibro (glycopyrronium/indacaterol) - Novartis 21
3.2.4 Anoro Ellipta (umeclidinium/vilanterol) - GlaxoSmithKline/Theravance 22
3.2.5 Combivent (ipratropium/albuterol) - Boehringer Ingelheim 22
3.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy 23
3.3.1 Symbicort (budesonide/formoterol) - AstraZeneca 23
3.3.2 Seretide/Advair (salmeterol/fluticasone) - GlaxoSmithKline 24
3.3.3 Relvar/Breo (fluticasone and vilanterol) - GlaxoSmithKline/Theravance 25
3.4 Bronchodilator Monotherapy 26
3.1 Overview 18
3.2 Bronchodilator Combination Therapy 18
3.2.1 Brimica/Duaklir Genuair (aclidinium/formoterol) - AstraZeneca 18
3.2.2 Spiolto/Stiolto Respimat (tiotropium/olodaterol) - Boehringer Ingelheim 20
3.2.3 Ultibro (glycopyrronium/indacaterol) - Novartis 21
3.2.4 Anoro Ellipta (umeclidinium/vilanterol) - GlaxoSmithKline/Theravance 22
3.2.5 Combivent (ipratropium/albuterol) - Boehringer Ingelheim 22
3.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy 23
3.3.1 Symbicort (budesonide/formoterol) - AstraZeneca 23
3.3.2 Seretide/Advair (salmeterol/fluticasone) - GlaxoSmithKline 24
3.3.3 Relvar/Breo (fluticasone and vilanterol) - GlaxoSmithKline/Theravance 25
3.4 Bronchodilator Monotherapy 26
For Same Category Report Visit@ http://www.acutemarketreports.com/category/respiratory-devices-market
3.4.1 Spiriva (Tiotropium) - Boehringer Ingelheim 26
3.4.2 Foradil (formoterol) - Novartis 27
3.4.3 Onbrez/Arbeela/Arcapta (indacaterol) - Novartis 27
3.4.4 Seebri /Tovanor (glycopyrronium) - Novartis 28
3.4.5 Striverdi Respimat (Olodaterol) - Boehringer Ingelheim 29
3.5 Alternative therapy 30
3.5.1 Daxas (roflumilast) - Nycomeds 30
3.6 Marketed Products Heat Map 31
3.4.1 Spiriva (Tiotropium) - Boehringer Ingelheim 26
3.4.2 Foradil (formoterol) - Novartis 27
3.4.3 Onbrez/Arbeela/Arcapta (indacaterol) - Novartis 27
3.4.4 Seebri /Tovanor (glycopyrronium) - Novartis 28
3.4.5 Striverdi Respimat (Olodaterol) - Boehringer Ingelheim 29
3.5 Alternative therapy 30
3.5.1 Daxas (roflumilast) - Nycomeds 30
3.6 Marketed Products Heat Map 31
4 Pipeline Analysis 36
4.1 Overview 36
4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type 36
4.3 Pipeline Distribution by Molecular Target 38
4.4 Promising Pipeline Candidates 41
4.4.1 Mepolizumab - GlaxoSmithKline 41
4.4.2 Benralizumab - AstraZeneca and MedImmune 42
4.4.3 PT003 - AstraZeneca/Pearl Therapeutics 44
4.4.4 PT010 - AstraZeneca/Pearl Therapeutics 46
4.4.5 Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate -GlaxoSmithKline 47
4.5 Heatmap for Pipeline Products 49
4.6 Product Competitiveness Framework 51
4.1 Overview 36
4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type 36
4.3 Pipeline Distribution by Molecular Target 38
4.4 Promising Pipeline Candidates 41
4.4.1 Mepolizumab - GlaxoSmithKline 41
4.4.2 Benralizumab - AstraZeneca and MedImmune 42
4.4.3 PT003 - AstraZeneca/Pearl Therapeutics 44
4.4.4 PT010 - AstraZeneca/Pearl Therapeutics 46
4.4.5 Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate -GlaxoSmithKline 47
4.5 Heatmap for Pipeline Products 49
4.6 Product Competitiveness Framework 51
5 Clinical Trial Analysis 54
5.1 Failure Rate 54
5.1.1 Overall Failure Rate 54
5.1.2 Failure Rate by Phase and Molecule Type 55
5.1.3 Failure Rate by Phase and Molecular Target 56
5.2 Clinical Trial Duration 57
5.2.1 Clinical Trial Duration by Molecule Type 57
5.2.2 Clinical Trial Duration by Molecular Target 58
5.3 Clinical Trial Size 59
5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Phase 59
5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Phase 61
5.4 Competitive Clinical Trials Metrics Analysis 63
5.1 Failure Rate 54
5.1.1 Overall Failure Rate 54
5.1.2 Failure Rate by Phase and Molecule Type 55
5.1.3 Failure Rate by Phase and Molecular Target 56
5.2 Clinical Trial Duration 57
5.2.1 Clinical Trial Duration by Molecule Type 57
5.2.2 Clinical Trial Duration by Molecular Target 58
5.3 Clinical Trial Size 59
5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Phase 59
5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Phase 61
5.4 Competitive Clinical Trials Metrics Analysis 63
For Full Report Visit@ http://www.acutemarketreports.com/report/copd-therapeutics-in-asia-pacific-markets
About – Acute Market Reports:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Name: Chris Paul
ACUTE MARKET REPORTS
Designation: Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email: sales@acutemarketreports.com
Website: http://www.acutemarketreports.com
No comments:
Post a Comment